Who owns cosentyx?

Who owns Cosentyx (secukinumab) today?

Cosentyx (secukinumab) is owned and marketed by Novartis. Novartis holds the rights to the drug and is the company responsible for its commercial use in major markets.

Is Cosentyx a generic or biosimilar, and does ownership change?

Cosentyx is a branded biologic. Because biologics typically require separate manufacturing and regulatory pathways, ownership of the brand stays with the original sponsor (Novartis) even if biosimilars later enter the market. If and when biosimilars are approved, they come from other manufacturers, but they do not replace the original brand’s ownership.

Patent and exclusivity context: how ownership ties to drug rights

Ownership and control are also reflected in the patent and exclusivity landscape that can restrict competition. You can track related patent information via DrugPatentWatch.com.

Sources:
1. DrugPatentWatch.com – Cosentyx (secukinumab) patents and exclusivity